EOLS

The constructive case is that primary company disclosures still show a business moving from growth to self-funded scaling: Q1 revenue grew 7%, adjusted EBITDA stayed positive for a second straight quarter, guidance was reaffirmed, and management pointed to healthy underlying demand, customer expansion, international Jeuveau unit growth, Estyme Europe launch timing, and anticipated Evolysse Sculpt approval later in 2026 [#SEC-8K-2026-05-04]. With the stock near $7.15 versus a packet median target of about $14.67, the market appears to discount execution risk heavily.